Denali Therapeutics Inc. - 8-K Filing
Denali Therapeutics Inc. held its annual stockholder meeting on June 3, 2026, where three Class III directors were elected with vote totals of Jennifer Cook (75,998,259), David Schenkein (91,814,688), and Ryan Watts (121,220,572). Stockholders also ratified the appointment of Ernst & Young LLP as auditors with 137,516,267 votes in favor. Additionally, they approved executive compensation on an advisory basis with 117,038,745 votes supporting it. (Items: 5.07 Submission of Matters to a Vote of Security Holders, 9.01 Financial Statements and Exhibits)
Tickers: $DNLI